Depression - Pipeline Review, H2 2014

Published: Oct, 2014 | Pages: 255 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Depression - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Depression - Pipeline Review, H2 2014', provides an overview of the Depression's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Depression, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Depression and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Depression
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Depression and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Depression products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Depression pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Depression
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 9
Introduction 10
Global Markets Direct Report Coverage 10
Depression Overview 11
Therapeutics Development 12
Pipeline Products for Depression - Overview 12
Pipeline Products for Depression - Comparative Analysis 13
Depression - Therapeutics under Development by Companies 14
Depression - Therapeutics under Investigation by Universities/Institutes 20
Depression - Pipeline Products Glance 22
Late Stage Products 22
Clinical Stage Products 23
Early Stage Products 24
Unknown Stage Products 25
Depression - Products under Development by Companies 26
Depression - Products under Investigation by Universities/Institutes 32
Depression - Companies Involved in Therapeutics Development 34
AB Science 34
Acetylon Pharmaceuticals, Inc. 35
Ache Laboratorios Farmaceuticos S/A 36
Adamas Pharmaceuticals, Inc. 37
Adamed Sp. z o.o. 38
Addex Therapeutics Ltd 39
Anavex Life Sciences Corp. 40
Angelini Group 41
Angita B.V. 42
ArisGen SA 43
Azevan Pharmaceuticals, Inc. 44
Beech Tree Labs, Inc. 45
BioCrea GmbH 46
Boehringer Ingelheim GmbH 47
Bristol-Myers Squibb Company 48
Calico LLC 49
Concert Pharmaceuticals, Inc. 50
Domain Therapeutics SA 51
Eisai Co., Ltd. 52
Eli Lilly and Company 53
GliaCure Inc. 54
Heptares Therapeutics Ltd. 55
Intra-Cellular Therapies, Inc. 56
Ironwood Pharmaceuticals, Inc. 57
Johnson & Johnson 58
KunWha Pharmaceutical Co., Ltd. 59
Luye Pharma Group Ltd. 60
M et P Pharma AG 61
Mapreg S.A.S. 62
MarcoPolo Pharmaceuticals SA 63
MI.TO. Technology S.r.L. 64
Mitsubishi Tanabe Pharma Corporation 65
Mnemosyne Pharmaceuticals, Inc. 66
Nektar Therapeutics 67
NeRRe Therapeutics Ltd 68
NeuroNascent, Inc. 69
Newron Pharmaceuticals S.p.A. 70
Pfizer Inc. 71
PsychoGenics, Inc. 72
Reviva Pharmaceuticals Inc. 73
Richter Gedeon Nyrt. 74
Saniona AB 75
SK Biopharmaceuticals Co., Ltd. 76
Supernus Pharmaceuticals, Inc. 77
Suven Life Sciences Ltd. 78
Taisho Pharmaceutical Co., Ltd. 79
Takeda Pharmaceutical Company Limited 80
Tetra Discovery Partners LLC 81
Trevena, Inc. 82
VistaGen Therapeutics , Inc. 83
Zhejiang Huahai Pharmaceutical Co., Ltd. 84
Depression - Therapeutics Assessment 85
Assessment by Monotherapy Products 85
Assessment by Target 86
Assessment by Mechanism of Action 90
Assessment by Route of Administration 93
Assessment by Molecule Type 95
Drug Profiles 97
ACY-738 - Drug Profile 97
ACY-775 - Drug Profile 98
ADN-2013 - Drug Profile 99
ADS-8800 Series - Drug Profile 100
ADX-92639 - Drug Profile 101
AFC-08 - Drug Profile 102
ALB-109780 - Drug Profile 103
Alstriol - Drug Profile 104
AMR-2 - Drug Profile 105
ANAVEX-1-41 - Drug Profile 107
AV-101 - Drug Profile 108
AVN-628 - Drug Profile 110
AZ-02 - Drug Profile 111
BCA-909 - Drug Profile 112
BLI-1005 - Drug Profile 114
BRL-44408 - Drug Profile 115
BTL-ng - Drug Profile 116
C-10068 - Drug Profile 117
C-187 - Drug Profile 118
CCG-63802 - Drug Profile 119
dehydroevodiamine hydrochloride - Drug Profile 120
dipraglurant IR - Drug Profile 121
Drug for Depression - Drug Profile 122
Drugs to Activate miR135 for Depression - Drug Profile 123
DT-2442 - Drug Profile 124
E-2508 - Drug Profile 125
etomoxir - Drug Profile 126
HTL-14242 - Drug Profile 128
Hydroxynorketamine - Drug Profile 129
IPX-237 - Drug Profile 130
ITI-007 - Drug Profile 131
IW-2143 - Drug Profile 133
JNJ-31020028 - Drug Profile 135
JNJ-47965567 - Drug Profile 136
JRP-227 - Drug Profile 137
JRP-362 - Drug Profile 138
KW-21072 - Drug Profile 139
LPM-570065 - Drug Profile 140
LY-05005 - Drug Profile 141
LY-2607540 - Drug Profile 142
MAP-4343 - Drug Profile 143
masitinib - Drug Profile 144
MIF-1 - Drug Profile 147
MIN-117 - Drug Profile 148
miR-135 - Drug Profile 149
MP-19 - Drug Profile 150
Next Generation Neurokinin-1 Receptor Antagonists for Depression - Drug Profile 151
NNI-351 - Drug Profile 152
NW-3509 - Drug Profile 153
P7-C3A20 - Drug Profile 154
progesterone - Drug Profile 156
PT-00114 - Drug Profile 157
PT-00121 - Drug Profile 158
PT-00211 - Drug Profile 159
PT-00411 - Drug Profile 160
REV-101 - Drug Profile 161
RGH-618 - Drug Profile 162
Rotem-201 - Drug Profile 164
RP-11000 - Drug Profile 165
Sazetidine-A - Drug Profile 166
SKL-N05 - Drug Profile 167
SKL-PSY - Drug Profile 169
Small Molecule to Activate Epsilon PKC for Depression - Drug Profile 170
Small Molecule to Activate Kappa Opioid Receptor for CNS - Drug Profile 171
Small Molecule to Activate LPL for CNS and Metabolic Disorders - Drug Profile 172
Small Molecule to Agonize Opioid Delta for Depression - Drug Profile 173
Small Molecule to Antagonize NMDA Receptor for Pain and Depression - Drug Profile 174
Small Molecule to Antagonize NR2B for Depression - Drug Profile 175
Small Molecule to Antagonize Vasopressin V1b Receptor for Depression - Drug Profile 176
Small Molecule to Block TREK for Depression - Drug Profile 177
Small Molecule to Inhibit Kappa Opioid Receptor for CNS - Drug Profile 178
Small Molecule to Inhibit PDE4 for Depression - Drug Profile 179
Small Molecule to Inhibit Serotonin-Norepinephrine-Dopamine Reuptake for Depression - Drug Profile 180
Small Molecule to Target 5HTT/5HT2C for CNS Disorders - Drug Profile 181
Small Molecule Triple Reuptake Inhibitors for Depression - Drug Profile 182
Small Molecules for Depression and Anxiety - Drug Profile 183
Small Molecules to Activate Delta Opioid Receptor for Immunology, CNS and Metabolic Disorders - Drug Profile 184
Small Molecules to Activate GABAA Receptor and Antagonize NMDA Receptor for CNS - Drug Profile 185
Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile 186
Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile 187
Small Molecules to Agonize Beta3-Adrenoceptor for Anxiety, Depression and Overactive Bladder - Drug Profile 189
Small Molecules to Agonize Delta Opioid Receptor for CNS Disorders - Drug Profile 190
Small Molecules to Agonize Mineralocorticoid Receptor for Depression and Anxiety - Drug Profile 191
Small Molecules to Antagonize CRHR1 for Depression and Anxiety Disorders - Drug Profile 192
Small Molecules to Antagonize mGluR1 for Depression - Drug Profile 193
Small Molecules to Antagonize NMDA Receptor 2B for Depression and Major Depressive Disorder - Drug Profile 194
Small Molecules to Block HCN1 Channels for Depression - Drug Profile 195
Small Molecules to Inhibit Amines Transport for Depression - Drug Profile 196
Small Molecules to Inhibit DAT and SERT for CNS Disorders - Drug Profile 197
Small Molecules to Inhibit mGluR7 For Central Nervous System Disorders - Drug Profile 198
Small Molecules to Inhibit TRPC4/C5 for Depression, Anxiety and Nephropathy - Drug Profile 199
SPN-809 - Drug Profile 200
SRX-251 - Drug Profile 201
STR-324 - Drug Profile 203
SUVN-90121 - Drug Profile 205
trazodone hydrochloride - Drug Profile 206
TS-111 - Drug Profile 207
UBP-608 - Drug Profile 208
Vaccine for PTSD and Depression - Drug Profile 209
VL-0919 - Drug Profile 210
VU-0092273 - Drug Profile 211
Depression - Recent Pipeline Updates 212
Depression - Dormant Projects 225
Depression - Discontinued Products 236
Depression - Product Development Milestones 239
Featured News & Press Releases 239
Appendix 247
Methodology 247
Coverage 247
Secondary Research 247
Primary Research 247
Expert Panel Validation 247
Contact Us 248
Disclaimer 248

List of Tables
Number of Products under Development for Depression, H2 2014 19
Number of Products under Development for Depression - Comparative Analysis, H2 2014 20
Number of Products under Development by Companies, H2 2014 22
Number of Products under Development by Companies, H2 2014 (Contd..1) 23
Number of Products under Development by Companies, H2 2014 (Contd..2) 24
Number of Products under Development by Companies, H2 2014 (Contd..3) 25
Number of Products under Development by Companies, H2 2014 (Contd..4) 26
Number of Products under Investigation by Universities/Institutes, H2 2014 28
Comparative Analysis by Late Stage Development, H2 2014 29
Comparative Analysis by Clinical Stage Development, H2 2014 30
Comparative Analysis by Early Stage Development, H2 2014 31
Comparative Analysis by Unknown Stage Development, H2 2014 32
Products under Development by Companies, H2 2014 33
Products under Development by Companies, H2 2014 (Contd..1) 34
Products under Development by Companies, H2 2014 (Contd..2) 35
Products under Development by Companies, H2 2014 (Contd..3) 36
Products under Development by Companies, H2 2014 (Contd..4) 37
Products under Development by Companies, H2 2014 (Contd..5) 38
Products under Investigation by Universities/Institutes, H2 2014 39
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 40
Depression - Pipeline by AB Science, H2 2014 41
Depression - Pipeline by Acetylon Pharmaceuticals, Inc., H2 2014 42
Depression - Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2014 43
Depression - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 44
Depression - Pipeline by Adamed Sp. z o.o., H2 2014 45
Depression - Pipeline by Addex Therapeutics Ltd, H2 2014 46
Depression - Pipeline by Anavex Life Sciences Corp., H2 2014 47
Depression - Pipeline by Angelini Group, H2 2014 48
Depression - Pipeline by Angita B.V., H2 2014 49
Depression - Pipeline by ArisGen SA, H2 2014 50
Depression - Pipeline by Azevan Pharmaceuticals, Inc., H2 2014 51
Depression - Pipeline by Beech Tree Labs, Inc., H2 2014 52
Depression - Pipeline by BioCrea GmbH, H2 2014 53
Depression - Pipeline by Boehringer Ingelheim GmbH, H2 2014 54
Depression - Pipeline by Bristol-Myers Squibb Company, H2 2014 55
Depression - Pipeline by Calico LLC, H2 2014 56
Depression - Pipeline by Concert Pharmaceuticals, Inc., H2 2014 57
Depression - Pipeline by Domain Therapeutics SA, H2 2014 58
Depression - Pipeline by Eisai Co., Ltd., H2 2014 59
Depression - Pipeline by Eli Lilly and Company, H2 2014 60
Depression - Pipeline by GliaCure Inc., H2 2014 61
Depression - Pipeline by Heptares Therapeutics Ltd., H2 2014 62
Depression - Pipeline by Intra-Cellular Therapies, Inc., H2 2014 63
Depression - Pipeline by Ironwood Pharmaceuticals, Inc., H2 2014 64
Depression - Pipeline by Johnson & Johnson, H2 2014 65
Depression - Pipeline by KunWha Pharmaceutical Co., Ltd., H2 2014 66
Depression - Pipeline by Luye Pharma Group Ltd., H2 2014 67
Depression - Pipeline by M et P Pharma AG, H2 2014 68
Depression - Pipeline by Mapreg S.A.S., H2 2014 69
Depression - Pipeline by MarcoPolo Pharmaceuticals SA, H2 2014 70
Depression - Pipeline by MI.TO. Technology S.r.L., H2 2014 71
Depression - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2014 72
Depression - Pipeline by Mnemosyne Pharmaceuticals, Inc., H2 2014 73
Depression - Pipeline by Nektar Therapeutics, H2 2014 74
Depression - Pipeline by NeRRe Therapeutics Ltd, H2 2014 75
Depression - Pipeline by NeuroNascent, Inc., H2 2014 76
Depression - Pipeline by Newron Pharmaceuticals S.p.A., H2 2014 77
Depression - Pipeline by Pfizer Inc., H2 2014 78
Depression - Pipeline by PsychoGenics, Inc., H2 2014 79
Depression - Pipeline by Reviva Pharmaceuticals Inc., H2 2014 80
Depression - Pipeline by Richter Gedeon Nyrt., H2 2014 81
Depression - Pipeline by Saniona AB, H2 2014 82
Depression - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2014 83
Depression - Pipeline by Supernus Pharmaceuticals, Inc., H2 2014 84
Depression - Pipeline by Suven Life Sciences Ltd., H2 2014 85
Depression - Pipeline by Taisho Pharmaceutical Co., Ltd., H2 2014 86
Depression - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 87
Depression - Pipeline by Tetra Discovery Partners LLC, H2 2014 88
Depression - Pipeline by Trevena, Inc., H2 2014 89
Depression - Pipeline by VistaGen Therapeutics , Inc., H2 2014 90
Depression - Pipeline by Zhejiang Huahai Pharmaceutical Co., Ltd., H2 2014 91
Assessment by Monotherapy Products, H2 2014 92
Number of Products by Stage and Target, H2 2014 94
Number of Products by Stage and Mechanism of Action, H2 2014 98
Number of Products by Stage and Route of Administration, H2 2014 101
Number of Products by Stage and Molecule Type, H2 2014 103
Depression Therapeutics - Recent Pipeline Updates, H2 2014 219
Depression - Dormant Projects, H2 2014 232
Depression - Dormant Projects (Contd..1), H2 2014 233
Depression - Dormant Projects (Contd..2), H2 2014 234
Depression - Dormant Projects (Contd..3), H2 2014 235
Depression - Dormant Projects (Contd..4), H2 2014 236
Depression - Dormant Projects (Contd..5), H2 2014 237
Depression - Dormant Projects (Contd..6), H2 2014 238
Depression - Dormant Projects (Contd..7), H2 2014 239
Depression - Dormant Projects (Contd..8), H2 2014 240
Depression - Dormant Projects (Contd..9), H2 2014 241
Depression - Dormant Projects (Contd..10), H2 2014 242
Depression - Discontinued Products, H2 2014 243
Depression - Discontinued Products (Contd..1), H2 2014 244
Depression - Discontinued Products (Contd..2), H2 2014 245